title: Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia.
authors.affiliation: Acute Leukemias and MDS, University of Texas MD, Anderson Cancer Center, Houston, Texas, USA. eheestey@mdanderson.org <eheestey@mdanderson.org>
authors.forename: Elihu
authors.initials: E
authors.lastname: Estey
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Sanz